Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
Phase 2
Not yet recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Shandong Public Health Clinical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06709859
- Locations
- 🇨🇳
Shandong Public Health Clinical Center, Jinan, Shandong, China
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer
Early Phase 1
- Conditions
- Advanced Primary Liver Cancer
- Interventions
- Combination Product: IBR900 combined with LenvatinibCombination Product: IBR900 combined with Bevacizumab
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Shandong Public Health Clinical Center
- Target Recruit Count
- 12
- Registration Number
- NCT05411757
© Copyright 2025. All Rights Reserved by MedPath